The PURAIR 5 Ductless Fume Hoods from Air Science USA feature a high level of operator protection where routine work is being carried out. The units exceed OSHA, ANSI and all relevant international standards.
Syrris will launch the Globe jacketed reactor platform at the Spring ACS Expo. This chemical reactor enables vessels from 50 mL to 5 L to use a common clamp, lid, circulator and stand.
AB SCIEX and Alturas Analytics Inc., a provider of LC/MS contract research services, announced a collaboration to accelerate the adoption of dried blood spot analysis for drug discovery & development.
Quanta Biosciences has developed hundreds of assays for quantifying microRNAs, and has entered into a partnership with Integrated DNA Technologies to custom manufacture them.
Giving critically ill patients antibiotics as a preventive measure significantly reduces the risk of infection with highly resistant microorganisms, according to the largest prospective study of topical preventive antibiotics in intensive care unit.
A team of scientists have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.
A new study demonstrates that Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases.
Scientists at Melbourne biotechnology company Hunter Immunology have developed a treatment for Chronic Obstructive Pulmonary Disorder, or COPD, which is being trialled on up to 340 patients at major hospitals around the country.
Swiss drug maker Novartis AG says it has received European Union approval to sell its oral multiple sclerosis medication Gilenya in the 27-nation bloc.
California has joined a whistleblower lawsuit that claims Bristol-Myers Squibb Co. bribed doctors to prescribe its drugs, costing insurers perhaps millions of dollars in the largest alleged health care fraud case ever handled by the state.
Anavex Life Sciences Corp. announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority.
Mucosis B.V. announced the start of a Phase 1 clinical study with its lead product FluGEM, a novel improved influenza vaccine for the elderly. It is the vaccine candidate based on Mimopath, a platform for developing more potent vaccines.
The US Food and Drug Administration has approved Oxford BioMedica plc's investigational new drug application for the Phase 1/2a clinical development of StarGen, a novel gene-based treatment for Stargardt disease.
Cell Therapeutics, Inc. announced that it has initiated a randomized trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Genentech announced that a Phase 2 clinical study of its hedgehog pathway inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma, a particularly severe and debilitating form of skin cancer.